WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 17,150,000 shares of its common stock at a public offering price of $17.50 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be approximately $300.1 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about January 9, 2024, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 2,572,500 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Morgan Stanley, J.P. Morgan, Jefferies and Stifel are acting as joint book-running managers for the offering. Oppenheimer & Co. and Raymond James are acting as co-managers for the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission ("SEC") and a related registration statement that was filed with the SEC on January 4, 2024 pursuant to Rule 462(b) under the Securities Act of 1933 (and became automatically effective upon filing). This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statements. A preliminary prospectus supplement relating to and describing the terms of ...